315 related articles for article (PubMed ID: 29148847)
1. Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas.
Orlova A; Wingelhofer B; Neubauer HA; Maurer B; Berger-Becvar A; Keserű GM; Gunning PT; Valent P; Moriggl R
Expert Opin Ther Targets; 2018 Jan; 22(1):45-57. PubMed ID: 29148847
[TBL] [Abstract][Full Text] [Related]
2. [Molecularly pathogenesis and molecular targeted therapy for myeloproliferative neoplasms].
Shide K
Rinsho Ketsueki; 2015 Feb; 56(2):150-8. PubMed ID: 25765794
[TBL] [Abstract][Full Text] [Related]
3. JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.
Kleppe M; Kwak M; Koppikar P; Riester M; Keller M; Bastian L; Hricik T; Bhagwat N; McKenney AS; Papalexi E; Abdel-Wahab O; Rampal R; Marubayashi S; Chen JJ; Romanet V; Fridman JS; Bromberg J; Teruya-Feldstein J; Murakami M; Radimerski T; Michor F; Fan R; Levine RL
Cancer Discov; 2015 Mar; 5(3):316-31. PubMed ID: 25572172
[TBL] [Abstract][Full Text] [Related]
4. Rapid Molecular Profiling of Myeloproliferative Neoplasms Using Targeted Exon Resequencing of 86 Genes Involved in JAK-STAT Signaling and Epigenetic Regulation.
Magor GW; Tallack MR; Klose NM; Taylor D; Korbie D; Mollee P; Trau M; Perkins AC
J Mol Diagn; 2016 Sep; 18(5):707-718. PubMed ID: 27449473
[TBL] [Abstract][Full Text] [Related]
5. A rare case report of 8p11 myeloid and lymphoid neoplasm with FGFR1 abnormality in a young adult.
Shaaban H; Dabu J; Al-Rabi K; Gauchan D; Guron G
Ann Hematol; 2013 Jan; 92(2):285-6. PubMed ID: 22941307
[No Abstract] [Full Text] [Related]
6. Mutations in the JAK/STAT pathway genes and activation of the pathway, a relevant finding in nodal Peripheral T-cell lymphoma.
Manso R; Sánchez-Beato M; González-Rincón J; Gómez S; Rojo F; Mollejo M; García-Cosio M; Menárguez J; Piris MA; Rodríguez-Pinilla SM
Br J Haematol; 2018 Nov; 183(3):497-501. PubMed ID: 29076126
[No Abstract] [Full Text] [Related]
7. New directions in treating peripheral T-cell lymphomas (PTCL): leveraging epigenetic modifiers alone and in combination.
Ma H; O'Connor OA; Marchi E
Expert Rev Hematol; 2019 Mar; 12(3):137-146. PubMed ID: 30782038
[TBL] [Abstract][Full Text] [Related]
8. A p53-JAK-STAT connection involved in myeloproliferative neoplasm pathogenesis and progression to secondary acute myeloid leukemia.
Goyal H; Chachoua I; Pecquet C; Vainchenker W; Constantinescu SN
Blood Rev; 2020 Jul; 42():100712. PubMed ID: 32660739
[TBL] [Abstract][Full Text] [Related]
9. [Not Available].
Mosca M; Vertenoeil G; Toppaldoddi KR; Plo I; Vainchenker W
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S16-28. PubMed ID: 27494969
[TBL] [Abstract][Full Text] [Related]
10. Mining for JAK-STAT mutations in cancer.
Constantinescu SN; Girardot M; Pecquet C
Trends Biochem Sci; 2008 Mar; 33(3):122-31. PubMed ID: 18291658
[TBL] [Abstract][Full Text] [Related]
11. Clonal architecture evolution in Myeloproliferative Neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscape.
Maslah N; Benajiba L; Giraudier S; Kiladjian JJ; Cassinat B
Leukemia; 2023 May; 37(5):957-963. PubMed ID: 37002477
[TBL] [Abstract][Full Text] [Related]
12. [Role of LNK gene mutation in pathogenesis of myeloproliferative neoplasms-review].
Chen Y; Wu XQ; Han CS; Zhu P; Wei JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Oct; 21(5):1309-12. PubMed ID: 24156456
[TBL] [Abstract][Full Text] [Related]
13. JAK2 the future: therapeutic strategies for JAK-dependent malignancies.
LaFave LM; Levine RL
Trends Pharmacol Sci; 2012 Nov; 33(11):574-82. PubMed ID: 22995223
[TBL] [Abstract][Full Text] [Related]
14. Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.
Pasquier F; Cabagnols X; Secardin L; Plo I; Vainchenker W
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S23-35. PubMed ID: 25486952
[TBL] [Abstract][Full Text] [Related]
15. JAK-mutant myeloproliferative neoplasms.
Levine RL
Curr Top Microbiol Immunol; 2012; 355():119-33. PubMed ID: 21823028
[TBL] [Abstract][Full Text] [Related]
16. Investigational drugs for T-cell lymphoma.
Ghez D; Danu A; Ribrag V
Expert Opin Investig Drugs; 2016; 25(2):171-81. PubMed ID: 26576861
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic deregulated miR-375 contributes to the constitutive activation of JAK2/STAT signaling in myeloproliferative neoplasm.
Yin LH; Zheng XQ; Li HY; Bi LX; Shi YF; Ye AF; Wu JB; Gao SM
Leuk Res; 2015 Apr; 39(4):471-8. PubMed ID: 25666256
[TBL] [Abstract][Full Text] [Related]
18. From empiric to mechanism-based therapy for peripheral T cell lymphoma.
Intlekofer AM; Younes A
Int J Hematol; 2014 Mar; 99(3):249-62. PubMed ID: 24510453
[TBL] [Abstract][Full Text] [Related]
19. [Recent advances in molecular pathogenesis of myeloproliferative neoplasms].
Ikeda K
Rinsho Ketsueki; 2016 Feb; 57(2):156-64. PubMed ID: 26935633
[TBL] [Abstract][Full Text] [Related]
20. Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.
Lai SY; Johnson FM
Drug Resist Updat; 2010 Jun; 13(3):67-78. PubMed ID: 20471303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]